A multinational, randomized, phase III trial of XELIRI ( plus bevacizumab) versus FOLFIRI ( plus bevacizumab) as the second-line chemotherapy for metastatic colorectal cancer: Asian XELIRI project (AXEPT).

被引：0
|
作者：
Muro, Kei
Kim, Tae Won
Park, Young Suk
Uetake, Hiroyuki
Nishina, Tomohiro
Nozawa, Hiroaki
Matsumoto, Hiroshi
Yamazaki, Kentaro
Han, Sae-Won
Lee, Keun-Wook
Deng, Yanhong
Buyse, Marc E.
Satoh, Taroh
Ryoo, Baek-Yeol
Shen, Lin
Iwasa, Satoru
Morita, Satoshi
Sakamoto, Junichi
Xu, Rui-hua
机构：
[1] Aichi Canc Ctr Hosp, Nagoya, Aichi 464, Japan
[2] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Oncol, Seoul, South Korea
[3] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Div Hematol Oncol,Dept Med, Seoul, South Korea
[4] Tokyo Med & Dent Univ, Dept Surg Specialties, Tokyo, Japan
[5] Shikoku Canc Ctr, Matsuyama, Ehime, Japan
[6] Univ Tokyo, Dept Surg Oncol, Tokyo, Japan
[7] Tokyo Metropolitan Komagome Hosp, Tokyo, Japan
[8] Shizuoka Canc Ctr, Shizuoka, Japan
[9] Seoul Natl Univ, Coll Med, Dept Internal Med, Seoul Natl Univ Hosp,Canc Res Inst, Seoul 151, South Korea
[10] Seoul Natl Univ, Coll Med, Bundang Hosp, Seoul, South Korea
[11] Sun Yat Sen Univ, Affiliated Hosp 6, Dept Med Oncol, Guangzhou 510275, Guangdong, Peoples R China
[12] Int Inst Drug Dev, Cambridge, MA USA
[13] Osaka Univ, Grad Sch Med, Dept Frontier Sci Canc & Chemotherapy, Osaka, Japan
[14] Beijing Canc Hosp, Beijing, Peoples R China
[15] Natl Canc Ctr, Gastrointestinal Med Oncol Div, 1-1 Tsukiji 5 chome, Tokyo, Japan
[16] Kyoto Univ, Grad Sch Med, Dept Biomed Stat & Bioinformat, Kyoto, Japan
[17] Tokai Cent Hosp, Kakamigahara, Japan
[18] Sun Yat Sen Univ, Ctr Canc, Guangzhou 510275, Guangdong, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 04期
关键词：
D O I：
10.1200/jco.2016.34.4_suppl.tps780
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS780
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Comparative analysis of the effectiveness of second-line bevacizumab plus chemotherapy in second-line therapy in metastatic colorectal cancer.
    Smagulova, Kaldigul
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [42] A PHASE I/II STUDY OF TRI-WEEKLY XELIRI PLUS BEVACIZUMAB FOR JAPANESE PATIENTS WITH MCRC AS SECOND-LINE CHEMOTHERAPY (BIX STUDY)
    Yamaguchi, Tatsuro
    Hamamoto, Yasuo
    Nishina, Tomohiro
    Yamazaki, Kentaro
    Ura, Takashi
    Takako, Nakajima
    Goto, Ayumu
    Shimada, Ken
    Nakayama, Norisuke
    Sakamoto, Junichi
    Morita, Satoshi
    Yamada, Yasuhide
    ANNALS OF ONCOLOGY, 2012, 23 : 99 - 99
  • [43] FOLFIRI plus bevacizumab induction chemotherapy followed by bevacizumab or observation in metastatic colorectal cancer, a phase III trial (PRODIGE 9-FFCD 0802)
    Aparicio, Thomas
    Linot, Benjamin
    Le Malicot, Karine
    Bouche, Olivier
    Boige, Valerie
    Francois, Eric
    Ghiringhelli, Francois
    Legoux, Jean-Louis
    Ben Abdelghani, Meher
    Phelip, Jean-Marc
    Faroux, Roger
    Dahan, Laetitia
    Taieb, Julien
    Bedenne, Laurent
    DIGESTIVE AND LIVER DISEASE, 2015, 47 (04) : 271 - 272
  • [44] PRESPECIFIED SUBGROUP ANALYSES IN WJOG4407G TRIAL, A RANDOMIZED PHASE III TRIAL OF MFOLFOX6 PLUS BEVACIZUMAB VERSUS FOLFIRI PLUS BEVACIZUMAB IN FIRST-LINE TREATMENT FOR METASTATIC COLORECTAL CANCER
    Hiroshi, Tamagawa
    Kentaro, Yamazaki
    Koichi, Suyama
    Michio, Okabe
    Kazuya, Suzuki
    Nobuhiko, Seki
    Kentaro, Kawakami
    Mikio, Sato
    Yasuo, Takahashi
    Tomonori, Hirashima
    Masahide, Ebi
    Keisei, Taku
    Toshio, Otsuji
    Fumio, Tamura
    Eiji, Shinozaki
    Koji, Nakashima
    Kensei, Yamaguchi
    Masahiko, Ando
    Satoshi, Morita
    Narikazu, Boku
    Ichinosuke, Hyodo
    ANNALS OF ONCOLOGY, 2014, 25
  • [45] Impact of Anti-angiogenic Agents on Chemotherapy Efficacy in Patients With Metastatic Colorectal Cancer: Second-line FOLFIRI Plus Bevacizumab or Aflibercept
    Yamada, Yunami
    Matsuhashi, Nobuhisa
    Fujii, Hironori
    Makiyama, Akitaka
    Iihara, Hirotoshi
    Takahashi, Takao
    Watanabe, Daichi
    Kiyama, Shigeru
    Kobayashi, Ryo
    Suzuki, Akio
    Yoshida, Kazuhiro
    ANTICANCER RESEARCH, 2021, 41 (01) : 533 - 541
  • [46] The TRUSTY Study: A Randomized Phase 2/3 Study of Trifluridine/Tipiracil Plus Bevacizumab Versus Irinotecan and Fluoropyrimidine Plus Bevacizumab as Second-Line Treatment in Patients With Metastatic Colorectal Cancer
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (09) : 9 - 10
  • [47] A phase I/II study of biweekly XELIRI plus bevacizumab for patients with metastatic colorectal cancer as second-line chemotherapy (BIXER study): Reports of phase I part and interim analysis of phase II part.
    Suenaga, Mitsukuni
    Matsusaka, Satoshi
    Shinozaki, Eiji
    Mizunuma, Nobuyuki
    Hatake, Kiyohiko
    Yamaguchi, Toshiharu
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
  • [48] A phase II clinical trial of metformin combined with FOLFIRI plus bevacizumab as second-line therapy in patients with RAS-mutant metastatic colorectal cancer
    He, Wen-zhuo
    Jiang, Chang
    Yi, Jiahong
    Xue, Ju
    Yin, Zhao-feng
    Dong, Wen-jing
    Xia, Liang-Ping
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [49] Axitinib or bevacizumab (bev) plus FOLFOX or FOLFIRI as second-line therapy in patients (pts) with metastatic colorectal cancer (mCRC)
    Bendell, J. C.
    Tournigand, C.
    Bednarczyk, M.
    Swieboda-Sadlej, A.
    Chung, I.
    Barone, C.
    Tarazi, J. C.
    Rosbrook, B.
    Ricart, A. D.
    Sobrero, A. F.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [50] FOLFIRI plus bevacizumab as second-line therapy for metastatic colorectal cancer pretreated with oxaliplatin: a pooled analysis of published trials
    Beretta, Giordano Domenico
    Petrelli, Fausto
    Stinco, Sergio
    Cabiddu, Mary
    Ghilardi, Mara
    Squadroni, Michela
    Borgonovo, Karen
    Barni, Sandro
    MEDICAL ONCOLOGY, 2013, 30 (01)
12345